Previous 10 | Next 10 |
Poseida Therapeutics press release ( NASDAQ: PSTX ): Q2 GAAP EPS of -$0.69 beats by $0.08 . Revenue of $2.7M beats by $1.77M . For further details see: Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 PR Newswire Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies dir...
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-st...
Helius Medical Technologies ( HSDT ) -28% . Heart Test Laboratories ( HSCS ) -22% . Gannett ( GCI ) -20% on Q2 earnings release . Poseida Therapeutics ( PSTX ) -20% on pricing $70M stock offering . Kaspien Holdings ( KSPN ) ...
Poseida Therapeutics ( NASDAQ: PSTX ) shares plunged ~20% pre-market on Thursday after the biopharmaceutical company priced its underwritten public offering of 20M shares of its common stock at $3.50 per share. Gross proceeds are estimated to be ~$70M. In addition,...
Poseida Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering ...
Poseida Therapeutics ( NASDAQ: PSTX ) shares slid ~13% during extended trading on Wednesday after the biopharmaceutical company proposed a public offering of common stock. Terms of the offering are yet to be determined. Poseida expects to grant the underwriters a 3...
Poseida Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering pl...
Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida established a deal with Roche for allogeneic therapies targeting hematological malignancie...
Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Inc. Website:
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...